Chronic Urticaria After Six Months of Omalizumab: What Actually Comes Next
She is caring for her aging father most weekends and has stopped mentioning the hives to him at all. Six months on what used to be the guideline's top step, and the drug that changed the answer arrived while she was still on it.
Most weekends now belong to her father, whose health has been declining enough that she drives two hours each way to help him with groceries and appointments, and somewhere in the last several months she stopped mentioning her own hives to him at all — one more thing she didn't want him worrying about on top of everything else. Six months of standard-dose omalizumab, the guideline's own final step before things get genuinely unclear, has taken the edge off but left her with hives four to five days a week and occasional facial swelling that hasn't yet involved her airway.
What actually comes next is where the guideline itself goes quiet, and three real options sit on the table with three different kinds of uncertainty behind them: pushing her existing drug harder than its label dose, on real-world evidence rather than a dedicated trial; switching to a different class with genuine randomized trial support but its own monitoring burden; or remibrutinib, an oral BTK inhibitor approved in September 2025 for adults with CSU still symptomatic on antihistamines. She meets that indication as written. What she does not obviously match is the population REMIX-1 and REMIX-2 actually enrolled — patients refractory to antihistamines, not patients six months into a partial response on omalizumab — so the newest option is the one whose label fits her best and whose trials describe her least.
Her disease itself began fourteen months ago with no identifiable trigger, and beyond the urticaria she is otherwise healthy — normal thyroid studies, no autoimmune markers on repeat screening, blood pressure and renal function both stable through six months of omalizumab with no adverse effects attributed to the drug itself. That clean safety record matters directly to the decision in front of the group: whatever gets chosen next has to be weighed not against omalizumab having failed her, exactly, but against omalizumab having done real, partial, insufficient work, which is a genuinely different starting point than starting fresh with an entirely unresponsive patient.
Six months on the guideline's last approved step
Before we move to a different drug entirely, I'd want to rule out that she's just under-dosed. Real-world case series on omalizumab dose or interval escalation beyond 300mg monthly show real additional response in patients who look refractory at the standard dose — it's not a dedicated randomized trial, but it's a reasonable next step before starting over with something new.
I'd rather move to cyclosporine now. Grattan's randomized, placebo-controlled trial is real evidence specifically in antihistamine-refractory CSU, it's available and covered today, and she's already given omalizumab six full months at standard dose. Asking her to wait through an unproven dose escalation of the same drug feels like more of the same wait she's already been living with.
The real-world escalation data is worth knowing about, but 'not yet confirmed by a dedicated trial' is doing real work in that sentence — it's a reasonable next step for some patients, not obviously the better bet than a drug with trial evidence built for this exact refractory picture.
I want to correct the framing before we settle this, because the shelf changed under us. Remibrutinib was approved last September for adults with CSU still symptomatic on H1-antihistamines — it is prescribable today, and she meets that indication as written. Treating it as pipeline data would be answering a question that closed a year ago.
What I won't do is let approval stand in for evidence about her specifically. REMIX-1 and REMIX-2 enrolled antihistamine-refractory patients; they were not designed to tell us what happens in someone who has already had six months of real, partial response to omalizumab. Cyclosporine's trial evidence is older and smaller, but Grattan's population is closer to hers than REMIX's is. If we start cyclosporine today I want it started for that reason, not because anyone in this room still thinks the oral option isn't on the shelf.
Agreed: start cyclosporine with baseline and monitoring labs for renal function and blood pressure, discontinuing omalizumab given the plan to change mechanism rather than escalate its dose.
Not agreed, and stated as such rather than resolved: whether omalizumab dose escalation should have been tried first, and whether remibrutinib should have been started ahead of cyclosporine. The allergist's position wasn't overruled so much as outcompeted by an option whose trial population sits closer to hers; the pharmacologist's point that remibrutinib is approved and she qualifies for it was accepted by everyone and deferred rather than dismissed, with a formulary check filed this week so that if cyclosporine's monitoring burden proves unworkable the oral option is already cleared rather than newly discovered.